The DOI matches its Crossref record; 85 of the 86 references it cites were found in a registry or an index.
Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma?
Abstract
The discovery of somatic mutations in the gene encoding isocitrate dehydrogenase-1 (IDH1) in glioblastomas was remarkable because the enzyme was not previously identified with any known oncogenic pathway. IDH1 is mutated in up to 75% of grade II and grade III diffuse gliomas. Apart from acute myeloid leukaemia, other tumour types do not carry IDH1 mutations. Mutations in a homologous gene, IDH2, have also been identified, although they are much rarer. Although TP53 mutations and 1p/19q codeletions are mutually exclusive in gliomas, in both of these genotypes IDH1 mutations are common. IDH1 and IDH2 mutations are early events in the development of gliomas. Moreover, IDH1 and IDH2 mutations are a major prognostic marker for overall and progression-free survival in grade II-IV gliomas. Mutated IDH1 has an altered catalytic activity that results in the accumulation of 2-hydroxyglutarate. Molecularly, IDH1 and IDH2 mutations are heterozygous, affect only a single codon, and rarely occur together. Because IDH1 does not belong to a traditional oncogenic pathway and is specifically and commonly mutated in gliomas, the altered enzymatic activity of IDH1 may provide a fundamentally new understanding of diffuse glioma.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“One of the key molecular differences between primary and secondary glioblastoma is the presence of isocitrate dehydrogenase-1 (IDH1) mutations which are found in approximately 75% of secondary GBM but are rare in primary GBM [13].”
From The p53 Pathway in Glioblastoma (2018) · cites this paper as [13]
In the citing paper
“In contrast to wt-p53, GOF mut-p53 exhibits interactions with distinct transcription factors (e.g., NF-ɣ, SREBP, VDR, Sp1, ETS2, NFR2, p73, p63) that promote tumor initiation and progression [13,72,73,74,75,76,77].”
From The p53 Pathway in Glioblastoma (2018) · cites this paper as [13]
Citations
Cites
Jemal, A., Bray, F., Ferlay, J., Ward, E., & Forman, D. (2011) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 55,077
Global Cancer Statistics, 2002
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005) · CA A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.2.74 · Cited by 18,710
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
High Frequency of Mutations of the PIK3CA Gene in Human Cancers
Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A. F., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,448
The Consensus Coding Sequences of Human Breast and Colorectal Cancers
Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D. L., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,161
Patterns of somatic mutation in human cancer genomes
Greenman, C. D., Stephens, P., Smith, R., Dalgliesh, G. L., Hunter, C., Bignell, G. R., Davies, H. R., Teague, J. W., Butler, A. P., Stevens, C., et al. (2007) · Nature · doi:10.1038/nature05610 · Cited by 3,143
Recurring mutations found by sequencing an acute myeloid leukemia genome
Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903840 · Cited by 2,219
Weinberg, R. A., & Weinberg, R. A. (2006) · W.W. Norton eBooks · doi:10.1201/9780203852569 · Cited by 1,806
Research works printed but not linked: 1
- Yan, 2009, IDH1 and IDH2 mutations play a fundamental role in glioma development, Neuro Oncol, 11, 608
Cited by
Sorted by citations
Items 201–222 of 222
Tesileanu, C. M. S., Vallentgoed, W., Sanson, M., Taal, W., Clément, P. M., Wick, W., Brandes, A. A., Baurain, J. F., Chinot, O. L., Wheeler, H., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.12.10.419333
Self-citationLiu, S., Zhang, Y., Kong, Z., Jiang, C., Wang, Y., Zhao, D., You, H., Ma, W., & Feng, F. (2020) · Research Square · doi:10.21203/rs.3.rs-62323/v1
Amino Acid PET/MRI in Neuro-oncology
Shooli, H., Assadi, M., Nabavizadeh, S. A., & Aboian, M. (2021) · Springer eBooks · doi:10.1007/978-3-030-82367-2_14
Liu, S., Zhang, Y., Kong, Z., Jiang, C., Wang, Y., Zhao, D., You, H., Ma, W., & Feng, F. (2021) · Research Square · doi:10.21203/rs.3.rs-62323/v2
Rodríguez, F. J., & Bowers, D. C. (2014) · Molecular pathology library · doi:10.1007/978-1-4939-1830-0_4
van den Bent, M. J., Gravendeel, L. A. M., Gorlia, T., Kros, J. M., Lapre, L., Wesseling, P., Teepen, J. L. J. M., Idbaïh, A., Sanson, M., Smitt, P. A. E. S., et al. (2023) · doi:10.1158/1078-0432.c.6519810.v1
Self-citationMolecular Pathology of the Central Nervous System
Cotter, J. A., & Hattab, E. M. (2023) · Springer eBooks · doi:10.1007/978-3-031-35118-1_23
Rani, V. L., Kate, M. S., Gosain, R., Kumar, S. S., & Gopikonda, S. S. (2024) · National Journal of Laboratory Medicine · doi:10.7860/njlm/2024/67448.2845
Smrdel, A. C. Š., Podlešek, A., Markovič, J., Jereb, J., Vidmar, M. S., & Smrdel, U. (2024) · Journal of Psychosocial Oncology Research and Practice · doi:10.1097/or9.0000000000000134
Martinez, C., Kahan, J., Guiot, M. C., & Tsien, C. I. (2024) · Springer eBooks · doi:10.1007/978-3-031-67878-3_6
Anatomic Predilection of IDH-Mutant Gliomas: A Multi-Institutional Spatial AnalysisPreprint
Park, M., Weiss, H., Harake, E. S., Fang, C. S., Springer, A., Goff, N. K., Markert, J. E., Reinecke, D., Maarouf, N., Miller, A. M., et al. (2025) · medRxiv · doi:10.1101/2025.09.16.25333605
Kmiecik, J. (2013) · NORA - Norwegian Open Research Archives
Mercier, M.-C. (2018) · theses.fr (ABES) · doi:10.70675/273bcce1z8572z472ez9afbzca3fd562301c
Park, M., Weiss, H., Harake, E. S., Fang, C. S., Springer, A., Goff, N. K., Markert, J. E., Reinecke, D., Maarouf, N., Heiland, D. H., et al. (2026) · Neurosurgery · doi:10.1227/neu.0000000000004019
Zheng, K., Han, Q., Li, T., Liu, Z., Li, E., Liu, J., Wb, M., You, H. Z., Wang, Y., & Huo, L. (2026) · EJNMMI Research · doi:10.1186/s13550-026-01457-1
Uncovering G Protein‐Coupled Receptors: Novel Targets and Biomarkers for Predicting Glioma Prognosis
Yang, J., Zhang, D., Liu, D., Lin, D., & Wang, H. (2026) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.70438
The differential diagnosis of astrocytic neoplasms and its impact on treatment and prognosis
Dickerman, R. D., Mendoza, M., McClinton, M., Champion, G., Runnels, J., & Hudson, H. (2026) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2026.2688939
IDH-Mutant Diffuse Glioma: From Metabolic Origins to Targeted Therapy
Purkart, T. U. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15166387
Metadata
- Authors
- Kloosterhof, N. K., Bralten, L. B., Dubbink, H. J., French, P. J., & van den Bent, M. J.
- Affiliations
- Erasmus MC - Sophia Children’s Hospital (NL)
- Daniel den Hoed Kliniek (NL)
- Erasmus MC (NL)
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2011-01
- Volume
- 12
- Issue
- 1
- Pages
- 83-91
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W2084945856
- Cited by
- 222
- References
- 86
- Citations by year
- 2026: 7 · 2025: 4 · 2024: 10 · 2023: 6 · 2022: 12 · 2021: 19 · 2020: 21 · 2019: 10 · 2018: 11 · 2017: 12 · 2016: 12 · 2015: 17 · 2014: 19 · 2013: 20 · 2012: 17
- FWCI
- 2.36
- Type
- journal article
- Language
- en
- Update notices
- erratum (2010-10-01)
- Open access
- closed
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- IDH1, IDH1 mutation, IDH2 mutation, diffuse glioma, glioblastoma, 2-hydroxyglutarate, TP53 mutation, 1p/19q codeletion, prognostic factors, tumor progression, oncogenic signaling
- MeSH terms
- Brain Neoplasms, Codon, Glioma, Humans, Isocitrate Dehydrogenase, Mutation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
